Vertex Pharmaceuticals (VRTX) Stock: Buy, Sell, or Hold?
VRTX - Vertex Pharmaceuticals Inc
$504.73
-2.01 (-0.40%)
▼
5d:
-4.08%
30d:
-9.34%
90d:
-4.69%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 02, 2026
28d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Sep 30, 2026 at $527.98 · last confirmed Oct 2, 2026
Strength: 4.6/10
Get Alerted When VRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VRTX is fairly valued with market pricing in 4.1% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: VRTX is fairly valued with market pricing in 4.1% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$860.41
Based on 14.2% avg growth
INTRINSIC VALUE TODAY
$534.25
5.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VRTX is currently trading at $504.73, which is considered oversold relative to its 30-day fair value range of $511.01 to $542.39. From a valuation perspective, the stock is trading at a premium (Forward PE: 25.1) compared to its historical average (22.3). At these levels, the market is pricing in 4.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VRTX is in a strong uptrend. The price is currently testing key support at $499.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VRTX scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $571.39 (+13.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VRTX is in a strong uptrend. The price is currently testing key support at $499.95. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: VRTX scores 63/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $571.39 (+13.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$511.01 -
$542.39
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
91.2%
Protect Your Profits
Holding VRTX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (63/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($571.39)
- NEUTRAL: Market pricing in 4.1% annual earnings growth - fairly valued
- CAUTION: Bottoming setup, but lagging the sector by 24% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$511.01 -
$542.39
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$20.57
(4.1%)
Support & Resistance Levels
Support Level
$499.95
Resistance Level
$529.89
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
25.10
Wall Street Target
$571.39
(+13.2%)
Revenue Growth (YoY)
12.5%
Earnings Growth (YoY)
8.0%
Profit Margin
35.0%
Valuation Premium vs History
+4.1% premium
PE vs Historical
25.1 vs 22.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.1%
(market-implied from PE analysis)
1-Year Target
$525.42
(+4%)
2-Year Target
$546.97
(+8%)
3-Year Target
$569.39
(+13%)
3-Yr Target (if PE normalizes)
(PE: 25→22)
PE COMPRESSION
$505.81
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 25.1, Growth: 24.3%)
$970.06
(+92%)
Base:
(SPY PE: 20.4, Growth: 24.3%)
$788.31
(+56%)
Bear:
(PE: 17.3, Growth: 24.3%)
$670.07
(+33%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 29.74 | Current EPS (TTM): $17.04
Bull Case
$657.71
(+30%)
Analyst growth 18.0%, PE expands to 32.7
Base Case
$597.92
(+19%)
Market implied 18.0%, PE stable at 29.7
Bear Case
$344.58
(-32%)
Severe decline -20.0%, PE contracts to 25.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 04, 2026 9:04 AM ET
Data refreshes hourly during market hours. Next update: 10:04 AM
Data refreshes hourly during market hours. Next update: 10:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
23 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 73 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$28 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 58 HOLD |
Advanced VRTX Option Strategies
Professional options setups generated by AI based on today's VRTX price and gamma walls.
